Who is sponsoring NCT02195895?

NCT02195895 is sponsored by Northwestern University.

What condition does NCT02195895 study?

NCT02195895 studies Spinal Cord Injury, Bone Loss, Osteoporosis.

What drugs are being tested in NCT02195895?

Interventions: Alendronate, Calcium, Vitamin D.

What is the status of NCT02195895?

NCT02195895 is currently COMPLETED.

Last reviewed 2023-03-28 · How we verify

12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide

NCT02195895 Phase 2 COMPLETED Results posted

The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI). This study will also investigate 1) if alendronate therapy will increase bone strength in people with chronic SCI, 2) the number of participants with adverse events from alendronate, and 3) the effects of alendronate on serum markers of bone metabolism.

Details

Lead sponsor	Northwestern University
Phase	Phase 2
Status	COMPLETED
Enrolment	17
Start date	2014-04
Completion	2016-08-05

Conditions

Spinal Cord Injury
Bone Loss
Osteoporosis

Interventions

Alendronate
Calcium
Vitamin D

Primary outcomes

BMD of Total Hip by DXA — 12 months
The mean percent change in bone mineral density (BMD) of the hip after 12 months of treatment. BMD was evaluated by dual-energy X-ray absorptiometry (DXA). DXA scans measure bone density in different areas of the body using low-dose X-ray beams.

Countries

United States